Markets & Finance

CSFB Initiates Kosan With Outperform


CS First Boston initiates Kosan Biosciences (KOSN) coverage with outperform.

Analyst Michele Park says the company has two first-in-class anti-cancer drugs in Phase 1 and 2 trials in multiple settings. It is in a partnership with Roche to develop and commercialize its lead candidate KOS-862 (Epothiline D) in oncology, a proprietary polyketide drug discovery platform.

She notes all this potential for the development-stage company with over $200 million in market capitalization. She says KOS-862 is in two Phase 2 trials in second-line breast cancer and prostate cancer, and in many dose-escalating Phase 1b combination trials.

Park expects data from these studies to create positive catalysts for Kosan throughout 2005.


Burger King's Young Buns
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

 
blog comments powered by Disqus